The role of P-glycoprotein in drug resistance in multiple myeloma

References

• Anderson KC, Shaughnessy JD, Jr., Barlogie B, Harousseau JL, Roodman GD. Multiple myeloma. Hematology Am Soc Hematol Educ Program 2002:214–240.
   Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487–2498.
   PubMed Web of Science ®Google Scholar
• Wang TF, Ahluwalia R, Fiala MA, et al. The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide. Leuk Lymphoma 2013.
   Web of Science ®Google Scholar
• Hovstadius P, Lindhagen E, Hassan S, et al. Cytotoxic effect in vivo and in vitro of CHS 828 on human myeloma cell lines. Anticancer Drugs 2004;15:63–70.
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1770–1781.
   PubMed Web of Science ®Google Scholar
• Borrello I. Can we change the disease biology of multiple myeloma?Leuk Res 2012;36 Suppl 1:S3–12.
   Web of Science ®Google Scholar
• Buda G, Ricci D, Huang CC, et al. Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 2010;89:1133–1140.
   PubMed Web of Science ®Google Scholar
• Grogan TM, Spier CM, Salmon SE, et al. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993;81:490–495.
   PubMed Web of Science ®Google Scholar
• Kitazono M, Sumizawa T, Takebayashi Y, et al. Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst 1999;91:1647–1653.
   PubMed Web of Science ®Google Scholar
• Pace L, Catalano L, Del Vecchio S, et al. Washout of [99mTc] sestamibi in predicting response to chemotherapy in patients with multiple myeloma. Q J Nucl Med Mol Imaging 2005;49:281–285.
   PubMed Web of Science ®Google Scholar
• Lin B, Catley L, LeBlanc R, et al. Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo. Blood 2005;105:350–357.
   PubMed Web of Science ®Google Scholar
• Schwarzenbach H. Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma. Med Oncol 2002;19:87–104.
   PubMed Web of Science ®Google Scholar
• Mahadevan D. Will MDR-1/P-gp modulators provide clinical benefit in hematologic malignancies?Leuk Res 2006;30:1077–1078.
   PubMed Web of Science ®Google Scholar
• Carey SS, Gleason-Guzman M, Gokhale V, Hurley LH. Psorospermin structural requirements for P-glycoprotein resistance reversal. Mol Cancer Ther 2008;7:3617–3623.
   PubMed Web of Science ®Google Scholar
• Jamroziak K, Balcerczak E, Calka K, et al. Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma. Leuk Res 2009;33:332–335.
   PubMed Web of Science ®Google Scholar
• Wesierska-Gadek J. Major contribution of the multidrug transporter P-glycoprotein to reduced susceptibility of poly(ADP-ribose) polymerase-1 knock-out cells to doxorubicin action. J Cell Biochem 2005;95:1012–1028.
   PubMed Web of Science ®Google Scholar
• Kaye SB, Kerr DJ. Multidrug resistance: clinical relevance in haematological malignancies. Blood Rev 1991;5:38–41.
   PubMed Web of Science ®Google Scholar
• Shustik C, Dalton W, Gros P. P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation. Mol Aspects Med 1995;16:1–78.
   PubMed Web of Science ®Google Scholar
• Sonneveld P. Multidrug resistance in haematological malignancies. J Intern Med 2000;247:521–534.
   PubMed Web of Science ®Google Scholar
• Vossebeld PJ, Sonneveld P. Reversal of multidrug resistance in hematological malignancies. Blood Rev 1999;13:67–78.
   PubMed Web of Science ®Google Scholar
• Hawley TS, Riz I, Yang W, et al. Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1. Am J Hematol 2013;88:265–272.
   PubMed Web of Science ®Google Scholar
• Biscardi M, Teodori E, Caporale R, et al. Multidrug reverting activity toward leukemia cells in a group of new verapamil analogues with low cardiovascular activity. Leuk Res 2006;30:1–8.
   PubMed Web of Science ®Google Scholar
• Vangsted A, Klausen TW, Vogel U. Genetic variations in multiple myeloma II: association with effect of treatment. Eur J Haematol 2012;88:93–117.
   PubMed Web of Science ®Google Scholar
• Spagnuolo PA, Hu J, Hurren R, et al. The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma. Blood 2010;115:4824–4833.
   PubMed Web of Science ®Google Scholar
• Nakagawa Y, Abe S, Kurata M, et al. IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Hematol 2006;81:824–831.
   PubMed Web of Science ®Google Scholar
• Fonti R, Del Vecchio S, Zannetti A, et al. Functional imaging of multidrug resistant phenotype by 99mTc-MIBI scan in patients with multiple myeloma. Cancer Biother Radiopharm 2004;19:165–170.
   PubMed Web of Science ®Google Scholar
• Pilarski LM, Belch AR. Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma. Blood 1994;83:724–736.
   PubMed Web of Science ®Google Scholar
• Salmon SE, Grogan TM, Miller T, Scheper R, Dalton WS. Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. J Natl Cancer Inst 1989;81:696–701.
   PubMed Web of Science ®Google Scholar
• Aouali N, Eddabra L, Macadre J, Morjani H. Immunosuppressors and reversion of multidrug-resistance. Crit Rev Oncol Hematol 2005;56:61–70.
   PubMed Web of Science ®Google Scholar
• Lehnert M, Dalton WS, Roe D, Emerson S, Salmon SE. Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. Blood 1991;77:348–354.
   PubMed Web of Science ®Google Scholar
• Haimovitz-Friedman A, Kan CC, Ehleiter D, et al. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J Exp Med 1994;180:525–535.
   PubMed Web of Science ®Google Scholar
• Ford JM. Modulators of multidrug resistance. Preclinical studies.Hematol Oncol Clin North Am 1995;9:337–361.
   PubMed Web of Science ®Google Scholar
• Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999;39: 361–398.
   PubMed Web of Science ®Google Scholar
• Mi Q, Cui B, Silva GL, et al. Pervilleine A, a novel tropane alkaloid that reverses the multidrug-resistance phenotype. Cancer Res 2001;61:4030–4037.
   PubMed Web of Science ®Google Scholar
• Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001;58:931–959.
   PubMed Web of Science ®Google Scholar
• List AF, Kopecky KJ, Willman CL, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001;98: 3212–3220.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48–58.
   PubMed Web of Science ®Google Scholar
• Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000;11:265–283.
   PubMed Web of Science ®Google Scholar
• Krishna R, Mayer LD. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug resistant solid tumors. Cancer Res 1997;57:5246–5253.
   PubMed Web of Science ®Google Scholar
• Krishna R, McIntosh N, Riggs KW, Mayer LD. Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion. Clin Cancer Res 1999;5:2939–2947.
   PubMed Web of Science ®Google Scholar
• Krishna R, St.-Louis M, Mayer LD. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by coadministering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin. 2000. 131–141 p.
   Google Scholar
• Krishna R, Mayer LD. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors. Cancer Res 1997;57:5246–5253.
   PubMed Web of Science ®Google Scholar
• Krishna R, St-Louis M, Mayer LD. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin. Int J Cancer 2000;85:131–141.
   PubMed Web of Science ®Google Scholar
• Krishna R, McIntosh N, Riggs KW, Mayer LD. Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion. Clin Cancer Res 1999;5:2939–2947.
   PubMed Web of Science ®Google Scholar
• Mechetner EB, Roninson IB. Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci U S A 1992;89:5824–5828.
   PubMed Web of Science ®Google Scholar
• Pennock GD, Dalton WS, Roeske WR, et al. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst 1991;83:105–110.
   PubMed Web of Science ®Google Scholar
• Bohme M, Buchler M, Muller M, Keppler D. Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane. FEBS Lett 1993;333:193–196.
   PubMed Web of Science ®Google Scholar
• Lum BL, Gosland MP. MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol Oncol Clin North Am 1995;9:319–336.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Lum BL, Fisher GA, et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1994;12:835–842.
   PubMed Web of Science ®Google Scholar
• Giaccone G, Linn SC, Welink J, et al. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res 1997;3:2005–2015.
   PubMed Web of Science ®Google Scholar
• Boote DJ, Dennis IF, Twentyman PR, et al. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 1996;14:610–618.
   PubMed Web of Science ®Google Scholar
• Sarris AH, Younes A, McLaughlin P, et al. Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin’s lymphoma. J Clin Oncol 1996;14:233–239.
   PubMed Web of Science ®Google Scholar
• Erlichman C, Moore M, Thiessen J, DeAngelis C, Goodman P, Manzo J. A phase I trial of doxorubicin (DOX) and PSC 833, a modulator of multidrug resistance (MDR): 97. Anticancer Drugs 1994;5:42.
   Google Scholar
• Watts GS, Futscher BW, Isett R, Gleason-Guzman M, Kunkel MW, Salmon SE. cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways. J Pharmacol Exp Ther 2001;299:434–441.
   PubMed Web of Science ®Google Scholar
• Kolesnick RN, Kronke M. Regulation of ceramide production and apoptosis. Annu Rev Physiol 1998;60:643–665.
   PubMed Web of Science ®Google Scholar
• Amiri-Kordestani L, Basseville A, Kurdziel K, Fojo AT, Bates SE. Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updat 2012;15:50–61.
   PubMed Web of Science ®Google Scholar
• Xu YC, Lin YM, Zhang FC. [The relationship between abnormal MDR gene expression and chemotherapy response in lymphoid malignancies]. Zhonghua Zhong Liu Za Zhi 2006;28:353–356.
   PubMedGoogle Scholar
• Yeh JJ, Hsu WH, Wang JJ, Ho ST, Kao A. Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression. Respiration 2003;70:32–35.
   PubMed Web of Science ®Google Scholar
• Chaudhary PM, Roninson IB. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 1993;85:632–639.
   PubMed Web of Science ®Google Scholar
• Juranka PF, Zastawny RL, Ling V. P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J 1989;3:2583–2592.
   PubMed Web of Science ®Google Scholar
• Ao L, Wu Y, Kim D, et al. Development of Peptide-Based Reversing Agents for P-Glycoprotein-Mediated Resistance to Carfilzomib. Mol Pharm 2012.
   PubMed Web of Science ®Google Scholar
• Verbrugge SE, Assaraf YG, Dijkmans BA, et al. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis. J Pharmacol Exp Ther 2012;341:174–182.
   PubMed Web of Science ®Google Scholar
• Rumpold H, Salvador C, Wolf AM, Tilg H, Gastl G, Wolf D. Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. Biochem Biophys Res Commun 2007;361:549–554.
   PubMed Web of Science ®Google Scholar
• Michaelis M, Fichtner I, Behrens D, et al. Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo. Int J Oncol 2006;28:439–446.
   PubMed Web of Science ®Google Scholar
• O’Connor R, Ooi MG, Meiller J, et al. The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. Cancer Chemother Pharmacol 2013;71:1357–1368.
   PubMed Web of Science ®Google Scholar
• Dalton WS, Grogan TM, Meltzer PS, et al. Drug-resistance in multiple myeloma and non-Hodgkin’s lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989;7:415–424.
   PubMed Web of Science ®Google Scholar
• Obaidat A, Weiss J, Wahlgren B, et al. Proteasome regulator marizomib (NPI-0052) exhibits prolonged inhibition, attenuated efflux, and greater cytotoxicity than its reversible analogs. J Pharmacol Exp Ther 2011;337:479–486.
   PubMed Web of Science ®Google Scholar
• Iijima M, Momose I, Ikeda D. Increased ABCB1 expression in TP-110-resistant RPMI-8226 cells. Biosci Biotechnol Biochem 2010;74:1913–1919.
   PubMed Web of Science ®Google Scholar
• Allegra A, Alonci A, Gerace D, et al. New orally active proteasome inhibitors in multiple myeloma. Leuk Res 2013.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Ocio EM, San Miguel JF. Novel generation of agents with proven clinical activity in multiple myeloma. Semin Oncol 2013;40:618–633.
   PubMed Web of Science ®Google Scholar
• Roovers DJ, van Vliet M, Bloem AC, Lokhorst HM. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines. Leuk Res 1999;23:539–548.
   PubMed Web of Science ®Google Scholar
• Bellamy WT, Dalton WS, Kailey JM, et al. Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. Cancer Res 1988;48:6365–6370.
   PubMed Web of Science ®Google Scholar
• Tsubaki M, Satou T, Itoh T, et al. Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrug-resistance in multiple myeloma cells. Leuk Res 2012;36:1315–1322.
   PubMed Web of Science ®Google Scholar
• Yang HH, Ma MH, Vescio RA, Berenson JR. Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis. J Clin Oncol 2003;21:4239–4247.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Suciu S, Weijermans P, et al. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). Br J Haematol 2001;115:895–902.
   PubMed Web of Science ®Google Scholar
• Mongkonsritragoon W, Kimlinger T, Ahmann G, Greipp PR. Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and amyloidosis?Leuk Lymphoma 1998;29:577–584.
   PubMed Web of Science ®Google Scholar
• Salmon SE, Dalton WS, Grogan TM, et al. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991;78:44–50.
   PubMed Web of Science ®Google Scholar
• Kuhne A, Tzvetkov MV, Hagos Y, Lage H, Burckhardt G, Brockmoller J. Influx and efflux transport as determinants of melphalan cytotoxicity: Resistance to melphalan in MDR1 overexpressing tumor cell lines. Biochem Pharmacol 2009;78:45–53.
   PubMed Web of Science ®Google Scholar
• Kofla G, Turner V, Schulz B, et al. Doxorubicin induces drug efflux pumps in Candida albicans. Med Mycol 2011;49:132–142.
   PubMed Web of Science ®Google Scholar
• Zhang J, Tian Q, Chan SY, Duan W, Zhou S. Insights into oxazaphosphorine resistance and possible approaches to its circumvention. Drug Resist Updat 2005;8:271–297.
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995;96:1698–1705.
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Tanaka H, Iwato K, et al. Effect of glucocorticoids on the biologic activities of myeloma cells: inhibition of interleukin-1 beta osteoclast activating factor-induced bone resorption. Blood 1990;75:715–720.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Witzig TE. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev 2000;26:351–362.
   PubMed Web of Science ®Google Scholar
• Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011;118:4771–4779.
   PubMed Web of Science ®Google Scholar
• Trussardi-Regnier A, Lavenus S, Gorisse MC, Dufer J. Thalidomide alters nuclear architecture without ABCB1 gene modulation in drug-resistant myeloma cells. Int J Oncol 2009;35:641–647.
   PubMed Web of Science ®Google Scholar
• Hus M, Dmoszynska A, Kocki J, et al. Long-term thalidomide therapy resulted in lack of mdr1 gene expression in a patient with primary resistant multiple myeloma. Leukemia 2005;19:1497–1499.
   PubMed Web of Science ®Google Scholar
• Beghin D, Delongeas JL, Claude N, Farinotti R, Forestier F, Gil S. Comparative effects of drugs on P-glycoprotein expression and activity using rat and human trophoblast models. Toxicol In Vitro 2010;24:630–637.
   PubMed Web of Science ®Google Scholar
• van de Donk NW, Gorgun G, Groen RW, et al. Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Manag Res 2012;4:253–268.
   PubMedGoogle Scholar
• Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133–2142.
   PubMed Web of Science ®Google Scholar
• Hofmeister CC, Yang X, Pichiorri F, et al. Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. J Clin Oncol 2011;29:3427–3434.
   PubMed Web of Science ®Google Scholar
• Takahashi N, Miura M, Kameoka Y, Abumiya M, Sawada K. Drug interaction between lenalidomide and itraconazole. Am J Hematol 2012;87:338–339.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, Swaika A, Paulus A, et al. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J 2013;3:e143.
   PubMed Web of Science ®Google Scholar
• Gay F, Mina R, Troia R, Bringhen S. Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma. Expert Opin Drug Metab Toxicol 2013;9:1517–1527.
   PubMed Web of Science ®Google Scholar